April 7, 2017
Sumitomo Dainippon Pharma said on April 6 that its Parkinson’s disease (PD) treatment Trerief (zonisamide) met the primary endpoint in a Japan PIII study covering patients with Parkinsonism in dementia with Lewy bodies. Based on the data, the company plans...read more